Substance
ID:347876
Names and Identifiers
Synonyms
CabaserDostinexFCE-213361-Ethyl-3-(3′-dimethylaminopropyl)-3-(6′-allylergoline-8′β-carbonyl)ureaCabergoline1-[(6-Allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea
IUPAC Traditional name
cabergoline
IUPAC name
1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carbonyl]urea
Properties
Safety Information
RTECS
KE6167600
MSDS Link
German water hazard class
3
GHS Hazard statements
H302-H315-H319-H335
GHS Precautionary statements
P261-P305+P351+P338
GHS Signal Word
Warning
Risk Statements
36/37/38
GHS Pictograms
Acute toxicity (oral, dermal, inhalation), category 4
Skin irritation, category 2
Eye irritation, category 2
Skin sensitisation, category 1
Specific Target Organ Toxicity – Single exposure, category 3
European Hazard Symbols
Irritant (Xi)Safety Statements
26-36/37
Storage Temperature
2-8°C
Product Information
Purity
≥98% (HPLC)
Empirical Formula (Hill Notation)
C26H37N5O2
Physical Property
Solubility
DMSO: ≥10 mg/mL
Apperance
powder
Molecule Details
Biochem/physiol Actions
Cabergoline, a lysergic acid amide derivative, is a potent dopamine D2 receptor agonist. It also acts on dopamine receptors in lactophilic hypothalamus cells to suppress prolactin production in the pituitary gland. It has been used for monotherapy of Parkinson′s disease in the early phase; combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson′s disease and adjunctive therapy of prolactin-producing pituitary gland tumors (microprolactinomas).
Cabergoline, a lysergic acid amide derivative, is a potent dopamine D2 receptor agonist. It also acts on dopamine receptors in lactophilic hypothalamus cells to suppress prolactin production in the pituitary gland. It has been used for monotherapy of Parkinson′s disease in the early phase; combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson′s disease and adjunctive therapy of prolactin-producing pituitary gland tumors (microprolactinomas).
Molecular Spectra
No Data Available
Click here to submit data
References
No Data Available
Click here to submit data